<?xml version="1.0" encoding="UTF-8"?>
<p>Supportive care and prevention of bacterial superinfection are the mainstay of management in patients with SARS-CoV-2 infection. Many off-label and compassionate-use pharmacologic therapies are being used without substantial evidence from high quality clinical studies and many of these treatments are currently undergoing evaluation in clinical trials.</p>
